Please go to the PowerPak homepage
and select a course.
Overcoming the Clinical Challenges of Basal Insulin Usage in Type 2 Diabetes
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Sanofi U.S.
May 5, 2017
May 5, 2018
This CE activity is based on a live symposium held on March 25, 2017. It features nationally recognized leaders in diabetes management and pharmacy practice, sharing the latest evidence and clinical practice pearls for community and health system pharmacists. It's organized into 4 sequential audio/slide-synched sections, each one lasting 12-25 minutes. The total is 1 hour and 23 minutes.
This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals with relevant issues/challenges in the management of patients with diabetes.
Upon completion of the educational activity, participants should be able to:
- Recognize the need for prompt and effective intervention in patients who are not achieving specified glycemic goals
- Apply strategies to reduce delayed insulin initiation, using recommended algorithms on appropriate timing, therapeutic sequence, titration and intensification of basal insulin therapy to achieve A1c goals
- Discuss practical knowledge of new concentrated basal insulins to ensure appropriate initiation (or conversion from previously utilized insulin titration), maintenance, concomitant use with other diabetes agents, and avoidance of adverse events (eg, hypoglycemia)
- Communicate, with patients, caregivers, and healthcare collaborators, effective ways to overcome challenges of basal insulin usage, including dosing, mitigating hypoglycemic events, weight gain, and injection techniques
Method of Participation
Statements of credit will be awarded based on the participant reviewing the entire presentation, scoring a 70% on the post test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at email@example.com. To fully understand and translate learning, AKH suggests the following methods of active learning for this activity:
- Develop a matrix to classify the at-risk patients and appropriate treatment therapy
- List situations where the different treatment options may be advantageous
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks
CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 1.5 contact hour(s) (0.15 CEUs). UAN 0077-9999-17-027-H04-P. Initial Release: 5/5/2017
This activity is supported by an educational grant from Sanofi US
There is no fee to participate in this activity.
Susan Cornell, PharmD, CDE, FAPhA, FAADE
Associate Director of Experiential Education
Chicago College of Pharmacy
Downers Grove, IL
Dr Cornell has disclosed the following relevant financial relationships:
Speakers Bureau - Novo Nordisk, Sanofi-aventis
Curtis L. Triplitt, PharmD, CDE
Diabetes Research Center
Texas Diabetes Institute
Associate Professor, Clinical
Department of Medicine, Division of Diabetes
University of Texas Health Science Center at San Antonio
San Antonio, TX
Dr Triplitt has disclosed the following relevant financial relationships:
Speakers Bureau - AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Janssen
Consultant - AstraZeneca, Novo Nordisk, Sanofi-aventis
AKH and Medtelligence planners and reviewers have no relevant financial relationships to disclose.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and Medtelligence specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of Medtelligence and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by Medtelligence and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
- A computer with an internet connection
- Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
- Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
Copyright © 2017 No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.